Tower Research Capital LLC (TRC) - ENTASIS THERAPEUTICS HLDGS I ownership

Quarter-by-quarter ownership
Tower Research Capital LLC (TRC) ownership history of ENTASIS THERAPEUTICS HLDGS I
ValueSharesWeighting
Q2 2022$5,000
-44.4%
2,426
-39.4%
0.00%
Q4 2021$9,000
-82.0%
4,000
-73.5%
0.00%
-100.0%
Q3 2021$50,000
+66.7%
15,093
+8.4%
0.00%0.0%
Q1 2021$30,000
+11.1%
13,918
+6.1%
0.00%
Q3 2020$27,000
+3.8%
13,120
+50.0%
0.00%
-100.0%
Q2 2020$26,000
+2500.0%
8,748
+6148.6%
0.00%
Q4 2019$1,0000.0%140
-24.3%
0.00%
Q3 2019$1,000
-88.9%
185
-87.3%
0.00%
-100.0%
Q2 2019$9,000
+28.6%
1,457
+35.2%
0.00%
Q1 2019$7,000
+16.7%
1,078
-22.9%
0.00%
Q4 2018$6,0001,3980.00%
Other shareholders
ENTASIS THERAPEUTICS HLDGS I shareholders Q3 2022
NameSharesValueWeighting ↓
FRAZIER MANAGEMENT LLC 1,349,953$8,046,0002.52%
Novo Holdings A/S 2,181,843$13,004,0002.23%
Sofinnova Investments, Inc. 1,180,178$7,034,0000.64%
TPG Group Holdings (SBS) Advisors, Inc. 2,041,496$12,168,0000.09%
Eventide Asset Management 392,513$2,288,0000.08%
Blackstone Inc. 1,623,405$9,675,0000.06%
Granahan Investment Management 141,012$840,0000.05%
Janney Montgomery Scott LLC 46,861$279,0000.00%
BANK OF MONTREAL /CAN/ 5,921$35,0000.00%
BlackRock Inc. 15,755$94,0000.00%
View complete list of ENTASIS THERAPEUTICS HLDGS I shareholders